NOVO NORDISK a/S

Explore how Novo Nordisk’s new drugs Frehemgo and Zaltenibart are redefining rare haemorrhagic care—boosting patient convenience, cutting costs, and driving high‑margin growth.

Novo’s rebranding and new AI partnership with Anthropic reveal a bold strategy to speed drug discovery, streamline trials, and stay ahead of generics.

Novo’s “Novo” rebrand fuels a pipeline from GLP‑1/GCGR dual agonists to CRISPR‑gene therapy, aiming to diversify beyond obesity and diabetes with fast‑track approvals.

Explore how Novo’s “Novo” rebrand and €15bn share‑repurchase plan strengthen its leadership in GLP‑1 obesity treatments, amid rising oral competition.

Novo Nordisk’s shares edge up despite a Berenberg downgrade, underscoring investor confidence in its GLP‑1 pipeline, tirzepatide prospects, and resilient diabetes revenue.

Novo Nordisk’s dual‑track plan—share‑buyback, AWS AI R&D and Wegovy’s German launch—boosts EPS, cuts drug‑development costs and captures high‑margin obesity therapy demand.